Efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO

Oreja-Guevara C., Benedict R. H., Comi G., Cutter G., Kister I., Siva A., ...More

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.327-329, (Summary Text)

  • Publication Type: Conference Paper / Summary Text
  • Volume: 28
  • City: Amsterdam
  • Country: Netherlands
  • Page Numbers: pp.327-329
  • Istanbul University Affiliated: Yes